Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study.
The aim of this study was to evaluate the therapeutic efficacy of intravenous immunoglobulin (IVIG) in the prevention of recurrent spontaneous abortion (RSA). In a double-blind, randomized, placebo-controlled study, 41 women with a history of unexplained recurrent spontaneous abortion were treated with IVIG or saline infusions during pregnancy. The birth of a child was considered a successful outcome. The overall success rate was 77% in the IVIG group compared with 79% in the placebo group. For women with primary RSA the success rates were 82 (IVIG) and 89% (placebo), and for women with secondary RSA the rates were 73 (IVIG) and 70% (placebo). We found no statistically significant difference in treatment results between IVIG and placebo.
Jablonowska
B
B
Department of Obstetrics and Gynecology, University Hospital, Linköping, Sweden.
Selbing
A
A
Palfi
M
M
Ernerudh
J
J
Kjellberg
S
S
Lindton
B
B
D000026:Abortion, Habitual / Q000517:prevention & control*; D001724:Birth Weight; D004311:Double-Blind Method; D005260:Female; D005865:Gestational Age; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000627:therapeutic use*; D007231:Infant, Newborn; D010919:Placebos; D011247:Pregnancy; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous; D010919:Placebos